Nuvalent Announces Public Offering of Common Stock - Yahoo …
WEB5 days ago · CAMBRIDGE, Mass., Sept. 16, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ...
Nuvalent Announces Publication in Cancer Discovery Detailing …
WEBSep 13, 2024 · Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...
Nuvalent Announces Closing of Upsized Public Offering of
WEB3 days ago · --Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its ...
News Releases - Nuvalent Investors
WEB3 days ago · Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results.
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation …
WEBFeb 27, 2024 · Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research ...
Riding high on ESMO data, Nuvalent reaps $500M in offering
WEB4 days ago · Sep. 17, 2024. Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million shares of class A common stock at $100 each. At the ESMO gathering in Barcelona, …
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 …
WEB4 days ago · Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant NSCLC. ... and a range of analysis and news reports to help Healthcare ...
NVL-655 Receives FDA Breakthrough Therapy Designation in …
WEBMay 17, 2024 · The FDA has granted breakthrough therapy designation to the investigational ALK-selective inhibitor NVL-655 as a treatment for patients with locally advanced or metastatic ALK -positive non–small cell lung cancer (NSCLC), according to a press release from the developers, Nuvalent, Inc. 1.
Nuvalent Announces Closing of Upsized Public Offering of …
WEB3 days ago · Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...
Nuvalent to Present New Preclinical Data on HER2-Selective …
WEBMar 5, 2024 · Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research ...